Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry Projected to Experience Accelerated Growth by 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Projected Growth Rate of the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Through 2030?
The warm autoimmune hemolytic anemia (waiha) treatment market size has grown strongly in recent years. It will grow from $0.6 billion in 2025 to $0.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to reliance on corticosteroid therapy, limited treatment options, hospital-based autoimmune care, blood transfusion dependency, low disease awareness.

The warm autoimmune hemolytic anemia (waiha) treatment market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to biologic drug innovation, improved autoimmune diagnostics, expansion of precision medicine, growing geriatric population, specialty hematology care growth. Major trends in the forecast period include increased use of monoclonal antibody therapies, rising adoption of steroid-sparing treatments, expansion of personalized autoimmune therapies, growing role of ivig in acute management, improved diagnostic and monitoring protocols.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/warm-autoimmune-hemolytic-anemia-waiha-treatment-global-market-report

What Are the Key Drivers of the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
The increasing healthcare expenditure is projected to fuel the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market going forward. Healthcare expenditure refers to the total amount of resources spent on health services, including prevention, diagnosis, treatment, and management of diseases, by individuals, governments, and organizations. Advancements in medical technology are driving up healthcare expenditure, as newer diagnostic tools and treatments often come with higher costs for development, implementation, and ongoing patient care. Healthcare expenditure supports warm autoimmune hemolytic anemia (WAIHA) treatment by funding research, providing access to advanced diagnostic tools, and ensuring the availability of specialized therapies that help manage and control the disease. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, in real terms, long-term health and social care expenditures increased by 2.8% in 2022, but overall healthcare spending increased by 5.6% in 2023. Therefore, the increasing healthcare expenditure is driving the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market.

How Is the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Segmented?
The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –

1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Children, Adults, Geriatric
4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib
3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins
4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions
5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy

Which Trends Are Most Likely to Influence Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Growth in the Next Decade?
Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are focusing on developing innovative solutions, such as monoclonal antibodies, to address the unmet clinical needs and improve patient outcomes. Monoclonal antibodies are lab-engineered proteins that target specific immune cells or pathways to reduce the destruction of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for IASO-782 Injection for use in clinical studies for autoimmune hematological conditions in the United States, such as warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). Targeting CD19, this fully human monoclonal antibody has Fc mutations to increase ADCC activity while maintaining other Fc functions. It selectively depletes CD19+ B cells, plasma blasts, and some plasma cells, which are responsible for producing auto-reactive antibodies. Due to its distinct mechanism, IASO-782 may be used to treat autoimmune illnesses that are caused by pathogenic B and plasma cells, such as ITP and AIHA.

Who Are the Emerging Players in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.

Get the full warm autoimmune hemolytic anemia (waiha) treatment market report here:
https://www.thebusinessresearchcompany.com/report/warm-autoimmune-hemolytic-anemia-waiha-treatment-global-market-report

How does market performance vary across key regions in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn